Article
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Oncogene - 8 Feb 2018
Chen S-H, Gong X, Zhang Y, Van Horn R D, Yin T, Huber L, Burke T F, Manro J, Iversen P W, Wu W, Bhagwat S V, Beckmann R P, Tiu R V, Buchanan S G, Peng S-B
Abstract excerpt
KRAS, NRAS and BRAF mutations are among the most important oncogenic drivers in many major cancer types, such as melanoma, lung, colorectal and pancreatic cancer. There is currently no effective therapy for the treatment of RAS mutant cancers. LY3009120, a pan-RAF and RAF dimer inhibitor advanced to clinical study has been shown to inhibit both RAS and BRAF mutant cell proliferation in vitro and xenograft tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.